
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. has demonstrated significant progress in its clinical programs, particularly with icovamenib, which reported a 1.2% reduction in HbA1c after 52 weeks in severe insulin-deficient Type 2 diabetes patients, indicating strong therapeutic efficacy. Additionally, the company has initiated Phase I trials for BMF-650, showing promising preclinical results in weight reduction and glycemic control, which enhances the potential for advancing its metabolic disease pipeline. Financially, Biomea Fusion has reduced its net loss from $32.8 million in Q3 2024 to $16.4 million in Q3 2025, reflecting improved capital efficiency as it simultaneously seeks to bolster its pipeline through an equity and warrant offering.
Bears say
Biomea Fusion Inc. reported a significant decrease in R&D expenses for Q3 2025, amounting to $14.4 million, compared to $27.2 million in Q3 2024, indicating a potential reduction in investment in critical drug development. Additionally, general and administrative (G&A) expenses also declined from $6.8 million to $4.2 million, reflecting a tightening of operational costs. The downward adjustment of the price target from $16.00 to $12.00 based on the new share count raises concerns about the company's growth prospects and overall financial health.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares